Neuroleptic	neuroleptic	O	B_disease
malignant	malignant	O	I_disease
syndrome	syndrome	O	I_disease
induced	induced	O	O
by	by	O	O
ziprasidone	ziprasidone	S_chemical	O
on	on	O	O
the	the	O	O
second	second	O	O
day	day	O	O
of	of	O	O
treatment	treatment	O	O
.	.	O	O

Neuroleptic	neuroleptic	O	B_disease
malignant	malignant	O	I_disease
syndrome	syndrome	O	I_disease
(	(	O	O
NMS	nms	O	O
)	)	O	O
is	is	O	O
the	the	O	O
rarest	rarest	O	O
and	and	O	O
most	most	O	O
serious	serious	O	O
of	of	O	O
the	the	O	O
neuroleptic-induced	neuroleptic-induced	O	O
movement	movement	O	B_disease
disorders	disorders	O	I_disease
.	.	O	O

We	we	O	O
describe	describe	O	O
a	a	O	O
case	case	O	O
of	of	O	O
neuroleptic	neuroleptic	O	B_disease
malignant	malignant	O	I_disease
syndrome	syndrome	O	I_disease
(	(	O	O
NMS	nms	O	O
)	)	O	O
associated	associated	O	B_disease
with	with	O	I_disease
the	the	O	O
use	use	O	O
of	of	O	O
ziprasidone	ziprasidone	S_chemical	O
.	.	O	O

Although	although	O	O
conventional	conventional	O	O
neuroleptics	neuroleptics	S_chemical	O
are	are	O	O
more	more	O	O
frequently	frequently	O	O
associated	associated	O	B_disease
with	with	O	I_disease
NMS	nms	O	O
,	,	O	O
atypical	atypical	O	O
antipsychotic	antipsychotic	B_chemical	O
drugs	drugs	I_chemical	O
like	like	O	O
ziprasidone	ziprasidone	S_chemical	O
may	may	O	O
also	also	O	O
be	be	O	O
a	a	O	O
cause	cause	O	O
.	.	O	O

The	the	O	O
patient	patient	O	O
is	is	O	O
a	a	O	O
24-year-old	24-year-old	O	O
male	male	O	O
with	with	O	O
a	a	O	O
history	history	O	O
of	of	O	O
schizophrenia	schizophrenia	O	S_disease
who	who	O	O
developed	developed	O	O
signs	signs	O	B_disease
and	and	O	I_disease
symptoms	symptoms	O	I_disease
of	of	O	O
NMS	nms	O	O
after	after	O	O
2	2	O	O
days	days	O	O
of	of	O	O
treatment	treatment	O	O
with	with	O	O
an	an	O	O
80-mg/day	80-mg/day	O	O
dose	dose	O	O
of	of	O	O
orally	orally	O	O
administrated	administrated	O	O
ziprasidone	ziprasidone	S_chemical	O
.	.	O	O

This	this	O	O
case	case	O	O
is	is	O	O
the	the	O	O
earliest	earliest	O	O
(	(	O	O
second	second	O	O
day	day	O	O
of	of	O	O
treatment	treatment	O	O
)	)	O	O
NMS	nms	O	O
due	due	O	O
to	to	O	O
ziprasidone	ziprasidone	S_chemical	O
reported	reported	O	O
in	in	O	O
the	the	O	O
literature	literature	O	O
.	.	O	O

